Earnings growth forecast for next year: Protagenic (PTIX)
Protagenic Therapeutics (PTIX) focuses on developing anxiety and depression therapies by controlling stress hormones. The business model relies on the high margins of mass-producing drugs following the completion of costly research. Preclinical tests are delegated to external centers while the company retains full patent ownership. The profit growth rate model for the coming year helps assess the asset's maturity, where the current value is 0.00.
Analytical breakdowns for Protagenic Therapeutics
- share price and consensus valuation forecast:
- company stock exchange capitalization indicators:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Protagenic Therapeutics|PTIX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Protagenic Therapeutics Inc.|PTIX - Aggregate Debt Obligations|Debt to Book Value Protagenic Therapeutics|PTIX - Amount of Long-Term Liabilities|Company Short-Term Debts Protagenic Therapeutics|Quick Ratio protagenic.com
- net income and valuation ratios data:
PTIX - Company Net Income|Expected Profit Protagenic Therapeutics|PTIX - Company Value to Net Income|Forward P/E Multiple Protagenic Therapeutics Inc.|PTIX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protagenic Therapeutics|PTIX - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Protagenic Therapeutics|PTIX - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months protagenic.com|PTIX - Earnings growth in current year|Expected earnings per share growth for next year Protagenic Therapeutics
- issuer revenue and sales details:
Fundamental company valuation:Protagenic Therapeutics
For an investor assessing the financial stability of an asset, this forward-looking earnings per share growth forecast reflects the dynamics of market expectation revisions regarding the company's future income. The indicator measures the percentage change in expected net profit, signaling a fundamental trend reversal. For Protagenic Therapeutics (PTIX), an increase in this metric would confirm the successful validation of peptides and the transition to a royalty-based model.
Direct competitors
BIIB (Biogen Corp) - Earnings growth forecast for next year|NBIX - Net earnings per one share growth forecast for next year|Earnings growth forecast for next year RGC|AXSM - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year ACADIA Pharmaceuticals Inc. ACAD|XENE: Projected earnings per share growth rate for next year|Viking Pharma - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Supernus Corp SUPN|CPRX: Earnings growth forecast for next year|Expected earnings per share growth for next year denalitherapeutics.com|Expected earnings per share growth for next year HRMY|BHVN: Expected earnings per share trend next year|Expected earnings per share growth for next year AMLX (Amylyx)|Projected earnings per share increase next year TRVI|Earnings growth forecast for next year PRAX (Praxis Precision Medicines)|Expected earnings per share trend next year AVXL|CeriBell - Earnings growth forecast for next year|Expected net earnings per share growth next year Prothena Corporation plc|alector.com (ALEC) - Net earnings per share growth forecast for next year|Annexon Biosciences Inc. - Expected earnings per share trend next year|OMER (Omeros Corp) - Earnings growth forecast for next year|Earnings growth forecast for next year neurogene.com|Net earnings per share growth forecast for next year AC Immune SA (ACIU)|VYGR: Net earnings per share change forecast for next year|Earnings growth forecast for next year NMRA (Neumora Therapeutics Inc)|Scilex Holding Company, Inc. (SCLX) - Expected net earnings per share growth next year|TVGN: Expected earnings per share growth for next year|ACOG - Earnings growth forecast for next year|CGTX (Cognition Therapeutics) - Expected earnings per share growth for next year|IKT: Projected earnings per share increase next year|SAVA (Cassava) - Earnings growth forecast for next year|Assertio Therapeutics (ASRT) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year COYA|Expected earnings per share growth for next year vistagen.com VTGN|Net earnings per share growth forecast for next year Ovid Therapeutics OVID|Consensus forecast of earnings per share growth for next year Acumen Pharmaceuticals Inc. (ABOS)|CRVO - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year ATHE|CLNN (clene.com) - Expected earnings per share growth for next year|PEPG: Projected earnings per share increase next year|JUNS (Jupiter Neurosciences Inc) - Earnings growth forecast for next year|Relmada Therapeutics Inc (RLMD) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year ANVS (Annovis Bio Corp)|gracetx.com - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year Firefly Neuroscience, Inc AIFF|KLTO: Projected earnings per share growth rate for next year|NeuroSense Therapeutics, Ltd. - Earnings growth forecast for next year|Expected net earnings per share growth next year Reviva Pharmaceuticals Holdings Inc.|MTVA (metaviatx.com) - Expected earnings per share growth for next year|NeurAxis Inc (NRXS) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Helius Medical Technologies, Inc.|PASG: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Neuphoria Therapeutics Inc. (NEUP)|NERV - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Athira ATHA|ADXN (Addex) - Net earnings per share change forecast for next year|ALZN - Net earnings per share growth forecast for next year|Expected earnings per share trend next year CYCN (Cyclerion Therapeutics)|pasitheaclinics.com (KTTA) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Cortigent (CRGT)|Expected earnings per share growth for next year ATXI|BCLI (BrainStorm Cell Therapeutics Inc.) - Projected earnings per share increase next year|Earnings growth forecast for next year CARA|Earnings growth forecast for next year chromocell.com (CHRO)|Earnings growth forecast for next year ELYM (Eliem Therapeutics Inc.)|Net earnings per one share growth forecast for next year Intra-Cellular Therapies Inc.|Longboard Pharma - Earnings growth forecast for next year|Expected net earnings per share growth next year Marinus Pharma|NKGen Biotech, Inc. (NKGN) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year NRBO|SAGE (Sage Therapeutics) - Earnings growth forecast for next year|Synaptogenix Inc. (SNPX) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year TRVN|Expected earnings per share growth for next year vigilneuro.com VIGL|Anew Medical - Expected earnings per share growth for next year|Expected earnings per share trend next year CERE
